MAIA Biotechnology, Inc. (MAIA)
- Previous Close
2.6800 - Open
2.7000 - Bid 2.9800 x 800
- Ask 3.1500 x 1400
- Day's Range
2.6510 - 3.0000 - 52 Week Range
0.8200 - 3.0700 - Volume
437,552 - Avg. Volume
324,442 - Market Cap (intraday)
60.51M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4900 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.63
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
www.MAIABiotech.comRecent News: MAIA
Performance Overview: MAIA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MAIA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MAIA
Valuation Measures
Market Cap
60.51M
Enterprise Value
60.31M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
126.72
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-3.05
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-128.79%
Return on Equity (ttm)
-440.12%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-19.77M
Diluted EPS (ttm)
-1.4900
Balance Sheet and Cash Flow
Total Cash (mrq)
7.15M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.42M